A review of binimetinib for the treatment of mutant cutaneous melanoma

References

• Chapman PB , HauschildA, RobertCet al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med.364(26), 2507–2516 (2011).
   PubMed Web of Science ®Google Scholar
• Flaherty KT , InfanteJR, DaudAet al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med.367(18), 1694–1703 (2012).
   PubMed Web of Science ®Google Scholar
• Hauschild A , GrobJJ, DemidovLVet al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase III randomised controlled trial. Lancet380(9839), 358–365 (2012).
   PubMed Web of Science ®Google Scholar
• Larkin J , AsciertoPA, DrenoBet al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med.371(20), 1867–1876 (2014).
   PubMed Web of Science ®Google Scholar
• Long GV , StroyakovskiyD, GogasHet al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, Phase III randomised controlled trial. Lancet386(9992), 444–451 (2015).
   PubMed Web of Science ®Google Scholar
• Robert C , KaraszewskaB, SchachterJet al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med.372(1), 30–39 (2015).
   PubMed Web of Science ®Google Scholar
• Schadendorf D , HodiFS, RobertCet al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol.33(17), 1889–1894 (2015).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network . Genomic classification of cutaneous melanoma. Cell161(7), 1681–1696 (2015).
   PubMed Web of Science ®Google Scholar
• Krauthammer M , KongY, BacchiocchiAet al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet.47(9), 996–1002 (2015).
   PubMed Web of Science ®Google Scholar
• Davies H , BignellGR, CoxCet al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JH , ChoiJW, KimYS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol.164(4), 776–784 (2011).
   PubMed Web of Science ®Google Scholar
• Raaijmakers MI , WidmerDS, NarechaniaAet al. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget7(47), 77163–77174 (2016).
   PubMedGoogle Scholar
• Johnson DB , MenziesAM, ZimmerLet al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer51(18), 2792–2799 (2015).
   PubMed Web of Science ®Google Scholar
• Dummer R , HauschildA, LindenblattN, PentheroudakisG, KeilholzU, CommitteeEG. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.26(Suppl. 5), v126–v132 (2015).
   PubMed Web of Science ®Google Scholar
• Garbe C , PerisK, HauschildAet al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016. Eur. J. Cancer63, 201–217 (2016).
   PubMed Web of Science ®Google Scholar
• Coit DG , ThompsonJA, AlgaziAet al. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw.14(4), 450–473 (2016).
   PubMed Web of Science ®Google Scholar
• Posch C , VujicI, MonshiBet al. Searching for the chokehold of NRAS mutant melanoma. J. Invest. Dermatol.136(7), 1330–1336 (2016).
   PubMed Web of Science ®Google Scholar
• Ascierto PA , SchadendorfD, BerkingCet al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label Phase II study. Lancet Oncol.14(3), 249–256 (2013).
   PubMed Web of Science ®Google Scholar
• Array Biopharma Inc . Investigator's Brochure Binimetinib (MEK162), Edition 12.1 (2016).
   Google Scholar
• Winski S , AndersonD, BouhanaKet al. MEK162 (ARRY-162), a Novel MEK 1/2 Inhibitor, Inhibits Tumor Growth Regardless of KRas/Raf Pathway Mutations. Presented at: 22nd EORTC-NCI-AACR symposium on Molecular targets and Cancer Therapeutics. Berlin, Germany, 27 May 2010.
   Google Scholar
• Bendell J , PapadopoulosK, JonesSet al. A Phase I Dose-Escalation Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Advanced Solid Tumors. Presented at: 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, CA, USA, 12–16 November 2011.
   Google Scholar
• Bendell JC , JavleM, Bekaii-SaabTSet al. A Phase I dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br. J. Cancer116(5), 575–583 (2017).
   PubMed Web of Science ®Google Scholar
• Finn RS , JavleMM, TanBRet al. A Phase I Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Biliary Tract Cancer. Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June 2012.
   Google Scholar
• Solit DB , GarrawayLA, PratilasCAet al. BRAF mutation predicts sensitivity to MEK inhibition. Nature439(7074), 358–362 (2006).
   PubMed Web of Science ®Google Scholar
• Van Herpen CM , AgarwalaSS, HauschildAet al. Overall Survival and Biomarker Results From a Phase II Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma. Presented at: European Society for Medical Oncology (ESMO) 2014 Congress. Madrid, Spain, 26–30 September 2014.
   Google Scholar
• Dummer R , SchadendorfD, AsciertoPAet al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, Phase III trial. Lancet Oncol.18(4), 435–445 (2017).
   PubMed Web of Science ®Google Scholar
• Dummer R , AsciertoPA, GogasHJet al. Results of COLUMBUS Part 1: A Phase III Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. Presented at: Society for Melanoma Research Thirteenth International Congress. Boston, MA, USA, 6–9 November 2016.
   Google Scholar
• Stuart DD , LiN, PoonDJet al. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research72(Suppl. 8), 2012 ( Abstract nr 3790).
   Google Scholar
• Dummer R , FlahertyKT, KeffordRet al. The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma. Presented at: HemOnc Today: Melanoma and Cutaneous Malignancies. New York, NY, USA, 11–12 April 2014.
   Google Scholar
• Sullivan RJ , WeberJS, PatelSPet al. A Phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. [abstract]. J. Clin. Oncol.33(Suppl.), 2015 ( Abstract 9007).
   PubMedGoogle Scholar
• Joseph RW , SullivanRJ, HarrellRet al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J. Immunother.35(1), 66–72 (2012).
   PubMed Web of Science ®Google Scholar
• Mangana J , ChengPF, SchindlerKet al. Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival? PLoS ONE 10(10), e0139438 (2015).
   PubMed Web of Science ®Google Scholar
• Ebert PJ , CheungJ, YangYet al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity44(3), 609–621 (2016).
   PubMed Web of Science ®Google Scholar
• Infante J , KimTM, FriedmannJet al. Safety and clinical activity of atezolizumab combined with cobimetinib in metastatic melanoma. Presented at: Society for Melanoma Research Thirteenth International Congress. Boston, MA, USA, 6–9 November 2016.
   Google Scholar
• Falchook GS , LongGV, KurzrockRet al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase I dose-escalation trial. Lancet379(9829), 1893–1901 (2012).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM , BastholtL, RobertCet al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res.18(2), 555–567 (2012).
   PubMed Web of Science ®Google Scholar
• Lebbe C , DutriauxC, LesimpleTet al. Pimasertib versus dacarbazine in patients with cutaneous NRAS melanoma: a controlled, open-label Phase II trial with crossover. Presented at: ESMO 2016 Congress. Ann. Oncol.27(6), 379–400, Copenhagen, Denmark (2016).
   Google Scholar
• Flaherty KT , RobertC, HerseyPet al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med.367(2), 107–114 (2012).
   PubMed Web of Science ®Google Scholar
• Eroglu Z , RibasA. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther. Adv. Med. Oncol.8(1), 48–56 (2016).
   PubMed Web of Science ®Google Scholar